|
|
Article: Other News To Note.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
o A.P. Pharma Inc., of Redwood City, Calif., initiated a Phase II program in cancer patients with its lead product candidate, APF530, for the prevention of acute and delayed chemotherapy-induced nausea and vomiting. APF530 was developed using the company's Biochronomer bioerodible drug delivery system with granisetron, one of a class of 5-HT3 antagonists, and is designed to provide therapeutic levels of the drug for four or five days of relief following a single subcutaneous injection. The trial will enroll patients undergoing moderately emetogenic chemotherapy, and the primary endpoints will be determining pharmacokinetics, safety and tolerability.
o Actimis ...